Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yukio Udagawa"'
Autor:
Hidehiro Tabata, Hiroyuki Kanno, Ayako Murayama, Tadashi Ishii, Ryosuke Harada, Yukio Udagawa
Publikováno v:
Renal Replacement Therapy, Vol 5, Iss 1, Pp 1-12 (2019)
Abstract Background This observational study investigated the safety and effectiveness of continuous erythropoietin receptor activator in patients with renal anemia in Japan. Methods Patients were enrolled between August 2011 and November 2015 and fo
Externí odkaz:
https://doaj.org/article/92db8728fd7c448aad3504999996fab7
Autor:
Hideki Kawanishi, Yoshiharu Tsubakihara, Yukio Udagawa, Kotonari Aoki, Masashi Suzuki, Yuzo Watanabe, Yasuo Ohashi, Takashi Akiba, Yoshiki Nishizawa, Masami Bessho, Yasuhiko Tomino, Yukari Uemura, Fumitake Gejyo, Akira Saito, Tadao Akizawa, Hideki Hirakata
Publikováno v:
Therapeutic Apheresis and Dialysis. 20:598-607
Progression of anemia in patients with chronic kidney disease (CKD) is associated with an increased risk of death and hospitalization. It is not sufficiently clear whether treating renal anemia with recombinant human erythropoietin (rHuEPO) has a ben
Autor:
Kana Yamada, Ichiro Konishi, Natsuko Miyawaki, Shinichi Matsuda, Yasuo Sugitani, Yukio Udagawa
Publikováno v:
Therapeutic innovationregulatory science. 50(6)
While benefit-risk (B-R) assessment in the real-world setting is an important challenge for pharmacovigilance, few studies have explored this approach. To investigate the utility and limitations of B-R assessment using a health care database by apply
Autor:
Yukari Uemura, Akira Saito, Yoshiki Nishizawa, Yasuhiko Tomino, Fumitake Gejyo, Masashi Suzuki, Hideki Kawanishi, Yuzo Watanabe, Yukio Udagawa, Yoshiharu Tsubakihara, Tadao Akizawa, Kotonari Aoki, Masami Bessho, Yasuo Ohashi, Takashi Akiba, Hideki Hirakata
Publikováno v:
Therapeutic Apheresis and Dialysis. 18:404-413
Although erythropoiesis-stimulating agents (ESAs) are effective at treating anemia, the association between hemoglobin (Hb) levels and survival is still unclear, especially for the incident Japanese hemodialysis (HD) population. The Japan Erythropoie
Autor:
Hideki Kawanishi, Kotonari Aoki, Hideki Hirakata, Yuzo Watanabe, Yukio Udagawa, Fumitake Gejyo, Yoshiki Nishizawa, Yasuhiko Tomino, Yasuo Ohashi, Takashi Akiba, Masami Bessho, Tadao Akizawa, Masashi Suzuki, Yukari Uemura, Yoshiharu Tsubakihara, Akira Saito
Publikováno v:
Therapeutic Apheresis and Dialysis. 18:140-148
The effect of recombinant human erythropoietin (rHuEPO) treatment on the progression of chronic kidney disease (CKD) has not been fully evaluated in Japan. We therefore retrospectively evaluated this in a sub-cohort of a prospective multicenter study
Autor:
Yuzo, Watanabe, Tadao, Akizawa, Akira, Saito, Fumitake, Gejyo, Masashi, Suzuki, Yoshiki, Nishizawa, Yasuhiko, Tomino, Yoshiharu, Tsubakihara, Takashi, Akiba, Hideki, Hirakata, Hideki, Kawanishi, Masami, Bessho, Yukio, Udagawa, Kotonari, Aoki, Yukari, Uemura, Yasuo, Ohashi
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 20(6)
Progression of anemia in patients with chronic kidney disease (CKD) is associated with an increased risk of death and hospitalization. It is not sufficiently clear whether treating renal anemia with recombinant human erythropoietin (rHuEPO) has a ben
Autor:
Tadao, Akizawa, Akira, Saito, Fumitake, Gejyo, Masashi, Suzuki, Yoshiki, Nishizawa, Yasuhiko, Tomino, Yoshiharu, Tsubakihara, Takashi, Akiba, Hideki, Hirakata, Yuzo, Watanabe, Hideki, Kawanishi, Masami, Bessho, Yukio, Udagawa, Kotonari, Aoki, Yukari, Uemura, Yasuo, Ohashi
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 18(2)
The effect of recombinant human erythropoietin (rHuEPO) treatment on the progression of chronic kidney disease (CKD) has not been fully evaluated in Japan. We therefore retrospectively evaluated this in a sub-cohort of a prospective multicenter study
Autor:
Tadao, Akizawa, Akira, Saito, Fumitake, Gejyo, Masashi, Suzuki, Yoshiki, Nishizawa, Yasuhiko, Tomino, Yoshiharu, Tsubakihara, Takashi, Akiba, Hideki, Hirakata, Yuzo, Watanabe, Hideki, Kawanishi, Masami, Bessho, Yukio, Udagawa, Kotonari, Aoki, Yukari, Uemura, Yasuo, Ohashi
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 18(5)
Although erythropoiesis-stimulating agents (ESAs) are effective at treating anemia, the association between hemoglobin (Hb) levels and survival is still unclear, especially for the incident Japanese hemodialysis (HD) population. The Japan Erythropoie
Publikováno v:
Drugs-Real World Outcomes
Background Measures of the effectiveness of risk minimization activities are necessary for the appropriate use of drugs, and clinical databases are a low-cost method of quickly producing such results. Objective The aim of this study was to explore th